A signature for immune response correlates with HCV treatment outcome in Caucasian subjects

por Hare, Brian J., Haseltine, Eric, Fleming, Mark, Chelsky, Daniel, McIntosh, Laura, Allard, Rene, Botfield, Martyn
Publicado 2015

Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaft...

por Tsai, Alice, Wu, Shu-Pei, Haseltine, Eric, Kumar, Sanjeev, Moskowitz, Samuel M., Panorchan, Paul, Shah, Kushal
Publicado 2020

Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial

por Davies, Jane C., Wainwright, Claire E., Sawicki, Gregory S., Higgins, Mark N., Campbell, Daniel, Harris, Christopher, Panorchan, Paul, Haseltine, Eric, Tian, Simon
Publicado 2021

Modeling Viral Evolutionary Dynamics after Telaprevir-Based Treatment

por Haseltine, Eric L., De Meyer, Sandra, Dierynck, Inge, Bartels, Doug J., Ghys, Anne, Davis, Andrew, Zhang, Eileen Z., Tigges, Ann M., Spanks, Joan, Picchio, Gaston, Kieffer, Tara L., Sullivan, James C.
Publicado 2014